1 2 3 schreef op 15 september 2015 12:42:
First Berlin – Pharming Group NV Research Update (10/08/2015)
10 Aug 2015 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and maintained his EUR 1.30 price target.
Abstract
Ruconest was launched on the key US market in November 2014. Q2/15 sales in the US came in at €2.4m - up from €0.6m in Q1/15. Overall company revenues were €3.5m (Q2/14: €1.1m). It is too early to assess Ruconest's likely US revenue trajectory based on only two quarters and management has not given any full year guidance. However, Pharming looks well placed to achieve our FY revenue forecast of EUR14.7m. Growing patient numbers, consistently positive feedback and Ruconest's lower risk profile relative to plasma-based therapies suggest a bright future for the product. We are leaving our forecasts largely unchanged and maintain our Buy recommendation and price target of €1.30.
-------------------------------------------------------------------------
- Stifel Nicolaus geeft koopadvies (Buy) voor Pharming
maandag 3 augustus 2015 - 23:00u -
Stifel Nicolaus geeft koopadvies (Buy) voor Pharming met een koersdoel van € 0,88
-------------------------------------------------------------------------
- KBC Securities verhoogt het houdadvies voor Pharming naar kopen (Accumulate)
donderdag 30 juli 2015 - 23:00u -
KBC Securities verhoogt het koersdoel van Pharming naar € 0,50 van € 0,40. Het houdadvies van donderdag 30 april 2015 wordt vervangen door een koopadvies. Dit vorige advies heeft geresulteerd in een rendement van 0,15%
kan even duren, maar dan heb je ook wat ....